Clarivate’s Epidemiology’s coverage of cystic fibrosis (CF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the birth incidence and…
Clarivate Epidemiology's coverage of cystic fibrosis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of cystic fibrosis…
Clarivate Epidemiology's coverage of Cystic Fibrosis (CF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CF for each…
Clarivate Epidemiology's coverage of Cystic Fibrosis (CF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CF for each…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key cystic fibrosis patient populations covering 171 countries and more…
Clarivate Epidemiology's coverage of Cystic Fibrosis (CF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CF for each…
Clarivate Epidemiology's coverage of Cystic Fibrosis (CF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CF for each…
Clarivate Epidemiology's coverage of Cystic Fibrosis (CF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CF for each…
MARKET OUTLOOK Idiopathic pulmonary fibrosis (IPF) is a type of lung disease characterized by the thickening and stiffening of tissues in the lungs. While the prognosis for patients diagnosed with…
Although Ofev and Esbriet are welcome options in the treatment armamentarium for idiopathic pulmonary fibrosis (IPF), therapies that can further delay or reverse the disease’s progression,…
Although Ofev and Esbriet are welcome options in the treatment armamentarium for idiopathic pulmonary fibrosis (IPF), therapies that can further delay or reverse the disease’s progression,…
Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and, ultimately, destruction of the interlobular bile ducts; this process is…
Non-alcoholic steatohepatitis (NASH) is a chronic disease that causes extensive and potentially fatal liver fibrosis; it is a leading cause of liver transplant. Significant increases in rates of…